Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Analysis depression: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older editNewer edit →
>Graham
Ref: Cannabis heavy usage = slower processing speed
>Graham
m Grammatics
Line 1: Line 1:
<onlyinclude>'''Analysis suppression''' can be described as a distinct decrease in a person's overall ability to process information<ref name="Knowles2010">Knowles, E. E., David, A. S., & Reichenberg, A. (2010). Processing speed deficits in schizophrenia: reexamining the evidence. American Journal of Psychiatry, 167(7), 828-835. https://doi.org/10.1176/appi.ajp.2010.09070937</ref><ref name="Takeuchi2013">Takeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., ... & Uchida, H. (2013). Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin, 39(5), 993-998. https://dx.doi.org/10.1093%2Fschbul%2Fsbt090</ref><ref name="Fried2005">Fried, P. A., Watkinson, B., & Gray, R. (2005). Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicology and teratology, 27(2), 231-239. https://doi.org/10.1016/j.ntt.2004.11.003</ref> and logically or creatively analyze concepts, ideas, and scenarios.<ref name="Kawai2006">Kawai, N., Yamakawa, Y., Baba, A., Nemoto, K., Tachikawa, H., Hori, T., ... & Iidaka, T. (2006). High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1009-1014. https://doi.org/10.1016/j.pnpbp.2006.03.013</ref> The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.  
<onlyinclude>'''Analysis suppression''' is a distinct decrease in a person's overall ability to process information<ref name="Knowles2010">Knowles, E. E., David, A. S., & Reichenberg, A. (2010). Processing speed deficits in schizophrenia: reexamining the evidence. American Journal of Psychiatry, 167(7), 828-835. https://doi.org/10.1176/appi.ajp.2010.09070937</ref><ref name="Takeuchi2013">Takeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., ... & Uchida, H. (2013). Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin, 39(5), 993-998. https://dx.doi.org/10.1093%2Fschbul%2Fsbt090</ref><ref name="Fried2005">Fried, P. A., Watkinson, B., & Gray, R. (2005). Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicology and teratology, 27(2), 231-239. https://doi.org/10.1016/j.ntt.2004.11.003</ref> and logically or creatively analyze concepts, ideas, and scenarios.<ref name="Kawai2006">Kawai, N., Yamakawa, Y., Baba, A., Nemoto, K., Tachikawa, H., Hori, T., ... & Iidaka, T. (2006). High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1009-1014. https://doi.org/10.1016/j.pnpbp.2006.03.013</ref> The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.  


Analysis suppression is often accompanied by other coinciding effects such as [[sedation]], [[thought deceleration]], and [[emotion suppression]]. It is most commonly induced under the influence of [[dosage#heavy|heavy]] [[dosage|dosages]] of [[antipsychotic]] compounds,<ref name="Knowles2010"/><ref name="Takeuchi2013"/><ref name="Kawai2006"/> and is associated with long term use of such drugs<ref>Husa, A. P., Moilanen, J., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I., ... & Koponen, H. (2017). Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry research, 247, 130-138. https://dx.doi.org/10.1016%2Fj.psychres.2016.10.085</ref> like [[quetiapine]], [[haloperidol]], and [[risperidone]]. However, it can also occur in a less consistent form under the influence of [[dosage#heavy|heavy]] dosages of [[dissociative|dissociatives]], [[cannabinoid|cannabinoids]],<ref name="Fried2005"/> and [[GABAergic|GABAergic]] [[depressant|depressants]]<ref>Paraherakis, A., Charney, D. A., & Gill, K. (2001). Neuropsychological functioning in substance-dependent patients. Substance use & misuse, 36(3), 257-271. https://doi.org/10.1081/JA-100102625</ref>.
Analysis suppression is often accompanied by other coinciding effects such as [[sedation]], [[thought deceleration]], and [[emotion suppression]]. It is most commonly induced under the influence of [[dosage#heavy|heavy]] [[dosage|dosages]] of [[antipsychotic]] compounds,<ref name="Knowles2010"/><ref name="Takeuchi2013"/><ref name="Kawai2006"/> and is associated with long term use of such drugs<ref>Husa, A. P., Moilanen, J., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I., ... & Koponen, H. (2017). Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry research, 247, 130-138. https://dx.doi.org/10.1016%2Fj.psychres.2016.10.085</ref> like [[quetiapine]], [[haloperidol]], and [[risperidone]]. However, it can also occur in a less consistent form under the influence of [[dosage#heavy|heavy]] dosages of [[dissociative|dissociatives]], [[cannabinoid|cannabinoids]],<ref name="Fried2005"/> and [[GABAergic|GABAergic]] [[depressant|depressants]]<ref>Paraherakis, A., Charney, D. A., & Gill, K. (2001). Neuropsychological functioning in substance-dependent patients. Substance use & misuse, 36(3), 257-271. https://doi.org/10.1081/JA-100102625</ref>.

Revision as of 04:49, 15 August 2018

Analysis suppression is a distinct decrease in a person's overall ability to process information[1][2][3] and logically or creatively analyze concepts, ideas, and scenarios.[4] The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.

Analysis suppression is often accompanied by other coinciding effects such as sedation, thought deceleration, and emotion suppression. It is most commonly induced under the influence of heavy dosages of antipsychotic compounds,[1][2][4] and is associated with long term use of such drugs[5] like quetiapine, haloperidol, and risperidone. However, it can also occur in a less consistent form under the influence of heavy dosages of dissociatives, cannabinoids,[3] and GABAergic depressants[6].

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

See also

References

  1. ↑ 1.0 1.1 Knowles, E. E., David, A. S., & Reichenberg, A. (2010). Processing speed deficits in schizophrenia: reexamining the evidence. American Journal of Psychiatry, 167(7), 828-835. https://doi.org/10.1176/appi.ajp.2010.09070937
  2. ↑ 2.0 2.1 Takeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., ... & Uchida, H. (2013). Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin, 39(5), 993-998. https://dx.doi.org/10.1093%2Fschbul%2Fsbt090
  3. ↑ 3.0 3.1 Fried, P. A., Watkinson, B., & Gray, R. (2005). Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicology and teratology, 27(2), 231-239. https://doi.org/10.1016/j.ntt.2004.11.003
  4. ↑ 4.0 4.1 Kawai, N., Yamakawa, Y., Baba, A., Nemoto, K., Tachikawa, H., Hori, T., ... & Iidaka, T. (2006). High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1009-1014. https://doi.org/10.1016/j.pnpbp.2006.03.013
  5. ↑ Husa, A. P., Moilanen, J., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I., ... & Koponen, H. (2017). Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry research, 247, 130-138. https://dx.doi.org/10.1016%2Fj.psychres.2016.10.085
  6. ↑ Paraherakis, A., Charney, D. A., & Gill, K. (2001). Neuropsychological functioning in substance-dependent patients. Substance use & misuse, 36(3), 257-271. https://doi.org/10.1081/JA-100102625
Retrieved from "http://psy.st/w/index.php?title=Analysis_depression&oldid=106145"